Dendritic cells (DC, antigen-presenting cells) are the initiators of the body’s anti-infection and anti-tumor immunity, specializing in the uptake, processing, handling and delivery of non-self-antigen information from bacteria, viruses and cancer cells to the next level of immune cells.
I. Basic principle of DC therapy
Bioimmune DC therapy for chronic hepatitis B virus infected patients obtains dendritic cells carrying hepatitis B virus antigens and functioning normally through bioimmune technology, and transfuses these cells back to patients, which can break the immune tolerance of the body’s immune system to hepatitis B virus, restart the recognition of hepatitis B virus, mobilize the immune system to fight against hepatitis B virus, achieve the inhibition of virus replication, promote the seroconversion of e antigen/antibody, and finally clear the virus and cure chronic hepatitis B virus. Finally, the virus is cleared and chronic hepatitis B is cured.
DC cells have strong anti-tumor activity and non-MHC-1 restricted tumor-killing characteristics, without harming any normal tissue cells. It can eliminate the residual tiny metastatic lesions, prevent tumor cells from spreading and recurrence, and improve the body’s own immunity at the same time.
Indications of Bioimmune DC Therapy
1.It is mainly applicable to the following chronic hepatitis B virus infected patients.
(1) Age between 16 and 65 years old.
(2) Patients with confirmed chronic hepatitis B and compensated cirrhosis.
(3) Aminotransferase (ALT) ≤ 400 U/L; total bilirubin (TBIL) ≤ 40umol/L.
(4) Those who have poor effect or rebound of antiviral therapy, including those who are resistant to antiviral drugs due to virus mutation.
(5) May be combined with other antiviral therapies such as interferon, lamivudine, adefovir, entecavir, etc.
(6) Women must not be pregnant or lactating, and patients of childbearing age must adhere to contraception when receiving treatment.
(7) Patients with hepatitis B cirrhosis in the compensated or mild to moderate decompensated phase
(8) Voluntary acceptance of treatment and signed informed consent.
Contraindications or relative contraindications
①Patients with severe chronic hepatitis B with significant jaundice, patients with severe hepatitis B and patients with significant decompensated hepatitis B cirrhosis.
②Patients with other chronic infectious diseases due to immune tolerance or immunodeficiency in combination.
③Patients with severe heart, lung, kidney and other organ diseases and patients with excessive physical weakness. Patients with combined tuberculosis, AIDS, psychiatric disorders and serious heart and kidney disorders, hematologic disorders, etc.
④Patients with hypersensitivity to multiple drugs or foods.
⑤Patients aged <12 years or >65 years.
⑥Bio therapy is not applicable to patients with T-cell lymphoma, those who use immunosuppressive drugs for a long time after organ transplantation, and patients with autoimmune diseases who are using immunosuppressive drugs.
III. Biological immune DC therapy methods.
1. DC cell vaccine therapy: once a month, appropriate amount of venous blood is drawn from the patient, stem cells in peripheral blood are isolated in the laboratory and then induced to be cultured into dendritic cells, which are injected into lymph nodes and around lymph, 6-12 times a course of treatment (applicable to hepatitis B).
2.DC cell transfusion therapy: 1-2 times in January, 10ml of peripheral blood is taken each time, the stem cells in peripheral blood are isolated in the laboratory, then induced and cultured into dendritic cells, and the cells are transfused back to the patient after 7 days, every 12 times is a course of treatment.
IV. Advantages of bioimmune DC therapy.
1, no side effects: there is a specific immune recognition function, which only has a killing effect on specific cells and no killing effect on normal tissue cells of the body
2, biological immunotherapy technology is very safe: treatment is the patient’s own blood cells, after the culture back to the transfusion will not occur immune rejection reaction.
3, biological immunotherapy technology is convenient and non-traumatic: the main treatment method of this technology is the autologous blood transfusion method, compared with traditional surgery, radiotherapy and chemotherapy methods do not exist any body trauma and discomfort.
4. Biological immunotherapy technology has remarkable effects.
(1)It can rapidly relieve the clinical symptoms of patients, and most patients can achieve the treatment effect of tumor shrinkage, ascites reduction or even disappearance or long-term survival with tumor, and improve the quality of life.
(2) It can significantly inhibit hepatitis B virus replication, rapidly reduce the number of hepatitis B virus, surface antigen and e antigen in the blood, promote the production of e antibody, and significantly accelerate the speed of e antigen/antibody seroconversion, with a total efficiency of more than 98% and the conversion of “major triple yang” to “minor triple yang The chance of conversion of “major tri-positive” to “minor tri-positive” and the chance of complete cure is much higher than that of drug treatment alone.
(3) To stimulate or mobilize the immune system of the body and enhance the anti-tumor immunity of tumor microenvironment, so as to control and kill tumor cells. It can not only kill the tumor in the patient’s body, but also enhance the patient’s immunity, improve the patient’s physique to improve the quality of life, and thus make some of the diseases caused by abnormal immunity to be relieved, which is a kind of treatment method with no long-term side effects and green.
V. Precautions
1. Possible adverse reactions of biological immunotherapy
Transient aminotransferase elevation is common, especially in patients who already have elevated aminotransferase, the elevation is usually more obvious after treatment. Mild cases can be left untreated, while those with significant elevation can be given liver protection therapy, and can generally return to normal within a few weeks.
Some patients may develop chills, fever, headache and generalized muscle aches 2-8 hours after infusion, similar to the flu-like symptoms that often occur after interferon injection. These symptoms usually resolve quickly with symptomatic treatment, such as oral antipyretics and analgesics.
Other rare adverse reactions, such as rash, anaphylaxis, autoimmune reactions and various infections, may occur. The total incidence of adverse reactions is less than 5%.
2.On the day of the infusion, especially the first few infusions, it is best for the patient to stay in the hospital for at least 6 hours to allow the doctor to observe and deal with possible adverse reactions.
3. In most cases, patients will not be affected by receiving biological immunotherapy. Because the adverse reactions of bioimmunotherapy are less and safer than the side effects of drug therapy, patients will not be affected by the adverse reactions in general.
Patients should pay attention to rest during bioimmunotherapy, do not work too hard, respond to the doctor in time if there is any discomfort, and come back on time to receive bioimmunotherapy or review the relevant indexes as required.